Delhi Medical Association honors leading Cardiologists for their outstanding contribution in the medical profession

Recognizing outstanding contribution in the field of healthcare technology, Delhi Medical Association, the oldest medical association in the world, felicitated Mr. Gurmit Singh Chugh and Ms. Punita Sharma Arora, with the DMA Special Award on the occasion of its centenary celebrations in the capital.  The Managing Directors of Translumina Therapeutics, both of them have played an instrumental role in creating indigenous high quality drug eluting stents for the Indian market thereby revolutionizing cardio-intervention in the country. The Union Minister of Finance & Defense, Shri Arun Jaitley, Union Health Minister, Dr. Harsh Vardhan and Minister of State for Science & Technology, Dr. Jitender Singh, presented the award.

Translumina Therapeutics partnered with German Heart centre, Munich and Translumina Gmbh, Germany to launch the first European Drug Eluting Stent made for the Indian market. Manufactured in the country, the stents are high quality, affordable and a lifesaving option for treatment of coronary heart disease.

Commenting on the occasion, Managing Directors of Translumina Therapeutics, Mr. Gurmit Singh Chugh and Ms. Punita Sharma Arora in a joint statementsaid,“It gives us immense pleasure to receive this prestigious award on the occasion of DMA’s centenary celebrations. At Translumina Therapeutics, it has been our constant endeavor to make quality healthcare more accessible and affordable for all. Our products are not only high quality and affordable but have proven to better that certain American manufactured products. We would like to congratulate all other awardees and hope we can all together make India a healthier and medically advanced nation”.

Translumina Therapeutics was incorporated with an objective of creating technologies, which help the physicians’ enhance their clinical outcomes whilst making it affordable for their patients. For the past few decades, most of the newer technologies launched in Interventional Cardiology were manufactured by US multinationals and came with an exorbitant price tag. Though revolutionary products, all these products were out of reach for a majority of the Indian population due to their cost factor. Realizing the need for affordable healthcare solutions suited to the Indian needs, Translumina Therapeutics was born and has been playing an active role in revolutionizing the treatment of coronary heart disease ever since.